Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146253 | 1.00 | HCRTR1 (0.39) | HCRTR1MGLLCCNKCDK12HCRTR2 | |
| SCHEMBL30408939 | 0.85 | MGLL (0.44) | HCRTR1MGLLCCNKCDK12 | |
| SCHEMBL25145740 | 0.85 | MGLL (0.44) | HCRTR1MGLLCCNKCDK12 | |
| SCHEMBL30409354 | 0.83 | MGLL (0.42) | MGLL | |
| SCHEMBL25145622 | 0.83 | MGLL (0.42) | MGLL | |
| SCHEMBL25324903 | 0.79 | CCNK (0.38) | HCRTR1MGLLCCNKCDK12 | |
| SCHEMBL30553201 | 0.79 | CCNK (0.38) | HCRTR1MGLLCCNKCDK12 | |
| SCHEMBL30408903 | 0.78 | MGLL (0.41) | MGLL | |
| SCHEMBL30699937 | 0.77 | CCNK (0.44) | HCRTR1CCNKCDK12 | |
| SCHEMBL30700041 | 0.77 | CCNK (0.44) | HCRTR1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | claimed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | claimed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | claimed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | disclosed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | HCRTR1 2560/4885MGLL 5/4885CCNK 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.